CY1121209T1 - Αντισωματα και εμβολια προς χρηση σε θεραπευτικες και διαγνωστικες μεθοδους για σχετιζομενες με αλφα-συνουκλεϊνη διαταραχες - Google Patents

Αντισωματα και εμβολια προς χρηση σε θεραπευτικες και διαγνωστικες μεθοδους για σχετιζομενες με αλφα-συνουκλεϊνη διαταραχες

Info

Publication number
CY1121209T1
CY1121209T1 CY20191100145T CY191100145T CY1121209T1 CY 1121209 T1 CY1121209 T1 CY 1121209T1 CY 20191100145 T CY20191100145 T CY 20191100145T CY 191100145 T CY191100145 T CY 191100145T CY 1121209 T1 CY1121209 T1 CY 1121209T1
Authority
CY
Cyprus
Prior art keywords
synuclein
syncline
vaccines
antibodies
alpha
Prior art date
Application number
CY20191100145T
Other languages
English (en)
Inventor
Lars Lannfelt
Joakim BERGSTRÖM
Martin Ingelsson
Pär GELLERFORS
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41020911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of CY1121209T1 publication Critical patent/CY1121209T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)

Abstract

Ένα εμβόλιο για την καθυστέρηση μιας έναρξης ή για τη θεραπευτική αγωγή μιας σχετιζόμενης με α-συνουκλεΐνη διαταραχής σε ένα άτομο περιλαμβάνει μια θεραπευτικώς αποτελεσματική ποσότητα απομονωμένου σταθεροποιημένου διαλυτού ολιγομερούς α-συνουκλεΐνης που έχει έναν χαμηλότερο ρυθμό σχηματισμού σε μια μη διαλυτή συσσωματωμένη μορφή από ότι ένα μη σταθεροποιημένο ολιγομερές της α-συνουκλεΐνης. Ένα αντίσωμα για την καθυστέρηση μιας έναρξης ή για τη θεραπευτική αγωγή μιας σχετιζόμενης με α-συνουκλεΐνη διαταραχής σε ένα άτομο προσδένει διαλυτή α-συνουκλεΐνη. Μέθοδοι για την καθυστέρηση μιας έναρξης, για τη θεραπευτική αγωγή ή για την πρόληψη μιας σχετιζόμενης με α-συνουκλεΐνη διαταραχής που χρησιμοποιούν το εμβόλιο ή αντίσωμα. Μέθοδοι ανίχνευσης ολιγομερών α-συνουκλεΐνης που χρησιμοποιούν το αντίσωμα.
CY20191100145T 2008-04-29 2019-01-31 Αντισωματα και εμβολια προς χρηση σε θεραπευτικες και διαγνωστικες μεθοδους για σχετιζομενες με αλφα-συνουκλεϊνη διαταραχες CY1121209T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4886508P 2008-04-29 2008-04-29
PCT/IB2009/051731 WO2009133521A2 (en) 2008-04-29 2009-04-28 Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders

Publications (1)

Publication Number Publication Date
CY1121209T1 true CY1121209T1 (el) 2020-05-29

Family

ID=41020911

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100145T CY1121209T1 (el) 2008-04-29 2019-01-31 Αντισωματα και εμβολια προς χρηση σε θεραπευτικες και διαγνωστικες μεθοδους για σχετιζομενες με αλφα-συνουκλεϊνη διαταραχες

Country Status (14)

Country Link
US (4) US8809506B2 (el)
EP (2) EP3470079A1 (el)
JP (2) JP5747414B2 (el)
CY (1) CY1121209T1 (el)
DK (1) DK2282758T3 (el)
ES (1) ES2709048T3 (el)
HR (1) HRP20190092T1 (el)
HU (1) HUE041223T2 (el)
LT (1) LT2282758T (el)
PL (1) PL2282758T3 (el)
PT (1) PT2282758T (el)
SI (1) SI2282758T1 (el)
TR (1) TR201901497T4 (el)
WO (1) WO2009133521A2 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US8546532B2 (en) 2008-04-17 2013-10-01 Declion Pharmaceuticals, Inc. Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
DK2448968T3 (da) * 2009-06-29 2021-04-12 Bioarctic Ab ANTISTOFFER SOM ER SELEKTIVE FOR N-TERMINAL-TRUNKEREDE AMYLOID-ß PROTOFIBRILLER/OLIGOMERER
EP2539366B1 (en) * 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
BR112013033258B1 (pt) 2011-06-23 2022-09-20 University Of Zurich Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos
PL2771031T3 (pl) 2011-10-28 2018-09-28 Prothena Biosciences Limited Co. Humanizowane przeciwciała rozpoznające alfa-synukleinę
CN104040342A (zh) * 2011-11-02 2014-09-10 生物国际强制戒毒协会国际神经系统科学公司 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
DK3166970T3 (da) 2014-07-10 2021-05-25 Bioarctic Ab FORBEDREDE Aß-PROTOFIBRILBINDENDE ANTISTOFFER
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
MY188183A (en) 2016-06-02 2021-11-24 Medimmune Ltd Antibodies to alpha-synuclein and uses thereof
RU2019102746A (ru) 2016-07-14 2020-08-14 Биоарктик Аб Белок для транспорта в мозг
JP7217229B2 (ja) 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
CN111225923B (zh) 2017-08-02 2024-09-24 思瑞麦科生物科技公司 结合活性α突触核蛋白的抗体
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP4273882A3 (en) 2017-12-19 2024-01-03 Chase Therapeutics Corporation Method for assessing a synucleinopathy
EP3773692A4 (en) * 2018-04-04 2022-03-16 University of Florida Research Foundation, Inc. SUBSTANCES AND METHODS FOR THE TREATMENT OF LEWY BODY DISORDERS
EP3845243A4 (en) * 2018-06-01 2022-04-27 National University Corporation Okayama University NOVEL MONOCLONAL ANTIBODIES WITH ANTI-INFLAMMATORY ACTIVITIES
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
JP7480180B2 (ja) * 2019-04-30 2024-05-09 チェイス セラピューティクス コーポレイション アルファ－シヌクレインアッセイ
IL294408A (en) 2019-12-31 2022-08-01 Chase Therapeutics Corp Kinases as biomarkers for neurodegenerative conditions
AU2021298222A1 (en) * 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies
CN112125832B (zh) * 2020-08-12 2022-09-20 北京大学 刺突蛋白受体结合结构域纳米凝胶及其制备方法与应用
AU2022233849A1 (en) * 2021-03-08 2023-10-12 Akershus Universitetssykehus Hf Clearance assay
WO2023210405A1 (ja) * 2022-04-25 2023-11-02 公益財団法人東京都医学総合研究所 変異型の神経変性疾患関連タンパク質

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255280T3 (es) 1998-07-03 2006-06-16 Innogenetics N.V. Diagnostico diferencial de la neurodegeneracion.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4820291B2 (ja) 2003-05-19 2011-11-24 エラン ファーマシューティカルズ，インコーポレイテッド レヴィー小体病におけるαシヌクレインの切断断片
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) * 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
EP1989330A4 (en) * 2006-01-31 2009-10-21 Elan Pharm Inc ALPHA-SYNUCLEINE KINASE
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DK3067066T3 (da) 2007-02-23 2019-05-20 Prothena Biosciences Ltd Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
EP2539366B1 (en) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Also Published As

Publication number Publication date
JP2011518874A (ja) 2011-06-30
EP3470079A1 (en) 2019-04-17
ES2709048T3 (es) 2019-04-15
US20110052498A1 (en) 2011-03-03
HUE041223T2 (hu) 2019-05-28
JP5747414B2 (ja) 2015-07-15
US20140335088A1 (en) 2014-11-13
HRP20190092T1 (hr) 2019-03-22
PT2282758T (pt) 2019-02-12
US20160199522A1 (en) 2016-07-14
JP2015057433A (ja) 2015-03-26
LT2282758T (lt) 2019-03-12
US8809506B2 (en) 2014-08-19
DK2282758T3 (en) 2019-02-25
WO2009133521A3 (en) 2010-04-01
US20200215209A1 (en) 2020-07-09
US9315569B2 (en) 2016-04-19
EP2282758A2 (en) 2011-02-16
WO2009133521A2 (en) 2009-11-05
EP2282758B1 (en) 2018-11-21
PL2282758T3 (pl) 2019-04-30
SI2282758T1 (sl) 2019-03-29
TR201901497T4 (tr) 2019-02-21

Similar Documents

Publication Publication Date Title
CY1121209T1 (el) Αντισωματα και εμβολια προς χρηση σε θεραπευτικες και διαγνωστικες μεθοδους για σχετιζομενες με αλφα-συνουκλεϊνη διαταραχες
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CY1124034T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-p
CY1120014T1 (el) Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1122269T1 (el) Νεες και ισχυρες μορφες δοσολογιας ταπενταδολης
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
CY1118090T1 (el) Αντιγονα ανασυνδυασμενου rsv
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
CY1124902T1 (el) Μεθοδοι αντιμετωπισης της υπερλιπιδημιας με αναστολεα angptl8 και αναστολεα angptl3
CY1118943T1 (el) Anti-pd-l1 αντισωματα και χρηση αυτων για την ενισχυση της λειτουργιας τ-κυτταρων
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
EA201490974A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
CY1116195T1 (el) Παραγοντες δεσμευσης του notch 1 υποδοχεα και μεθοδοι χρησης αυτων
MX2016008362A (es) Combinaciones farmaceuticas.
WO2012071554A3 (en) Anti-il-6 antibodies for the treatment of oral mucositis
CY1118543T1 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
WO2014127917A8 (en) Combination of vaccination and inhibition of the pd-1 pathway
DK1981981T3 (da) Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
DOP2006000277A (es) Anticuerpos anti mn y métodos para su utilización
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения